505 b(2) application & requirement of bio­equi­va­lence [Regulatives / Guidelines]

posted by Achievwin – US, 2023-05-05 18:08 (144 d 00:29 ago) – Posting: # 23546
Views: 744

Hello Mithu:

505 (b)(2) is all about the submission and marketing strategy. Most of the 505(b)(2) applications take BE route as drug Chemistry, safety and efficacy along with biopharmaceutics is already known and BE is used as a knowledge (claim) gap bridging approach. There are other means you can get 505(b)(2. Please review different guidance (FDA, EMA etc.) or white papers on 505(b)(2).

Hope this helps

Complete thread:

UA Flag
 Admin contact
22,761 posts in 4,775 threads, 1,628 registered users;
14 visitors (0 registered, 14 guests [including 6 identified bots]).
Forum time: 18:38 CEST (Europe/Vienna)

Whenever a theory appears to you as the only possible one,
take this as a sign that you have neither understood the theory
nor the problem which it was intended to solve.    Karl R. Popper

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz